| gap-pubmed-20260410- | What determines the kinetic preference for BID over MDM2 cleavage by caspase-2? | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does caspase-2-mediated centrosome surveillance prevent neurodegeneration in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does AMPK/SIRT1/PGC-1α pathway disruption manifest through different mechani | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines tissue-specific regulatory mechanisms of PGC-1α interactome dyna | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do AMPK isoform-specific functions differ across brain regions and neurodege | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Will ECM remodeling effects on memory and Aβ clearance persist long-term or requ | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ECM remodeling specifically activate MERTK receptor signaling in astroc | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link ECM remodeling to activation of the astrocytic au | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do functionally distinct reactive astrocyte sub-states contribute to the pat | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What triggers drive astrocytes to adopt specific reactive sub-states in disease? | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which reactive astrocyte sub-states are shared across different neurodegenerativ | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the proposed multi-target approaches for AD and PD interact synergistical | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which saffron phytochemicals enhan | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does vitamin C specifically target MAPK and NF-κB pathways but not other inf | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does vitamin C deficiency mechanistically link to neuroinflammation and neur | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular requirements for developing IGF2R-targeted thera | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does IGF2R deregulation mechanistically contribute to neurodegeneration and | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular pathways link particulate matter exposure to coordinated vesicula | open | 0.74 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do increased PNN components and proteolytic enzymes simultaneously coexist i | open | 0.77 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What mechanisms drive the temporal paradox of cognitive recovery despite continu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-pubmed-20260410- | Why do targeted treatments based on molecular alterations have limited efficacy | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | Why do some IDH-mutant glioma patients achieve long-term survival (>10-20 years) | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | How do CSF proteomic signatures mechanistically predict cognitive versus motor d | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do only 5 of 14 proteomic signature proteins retain diagnostic utility acros | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What biological mechanisms underlie the 14 CSF proteins that comprise the PD pro | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability | investigating | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-26 | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of E6AP-mediated degradation of lysine-modified | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does UBQLN2 ubiquitylation mechanistically regulate its phase separation and | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why can motor function recover despite irreversible motor neuron loss in this TD | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does cytoplasmic TDP-43 accumulation cause loss of nuclear TDP-43 function? | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable functional recovery and muscle re-innervation a | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does TOP2A suppression specifically restore anoikis sensitivity rather than | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of muscone's EGFR/Integrin β1/FAK pathway target | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does muscone selectively cross the blood-brain barrier while other similar c | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of MYCN, MEIS2, and HAND2 complex formation at t | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | How does AP-1 mechanistically regulate chromatin accessibility to expose IRF2BP2 | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | How does glymphatic tau clearance relate to neuron-to-neuron tau propagation pat | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does impaired glymphatic clearance cause tau accumulation or result from existin | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms cause tau pathology to impair AQP4 polarization and gl | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does metformin's myelin repair enhancement translate from young mice to aged or | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does metformin's metabolic modulation mechanistically drive AMPK-dependent O | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms explain metformin's opposite metabolic effects on OPCs | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the vicious cycle between oxidative stress, Aβ/tau pathology, and redox | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain how both hypoxia and hyperoxia lead to similar AD pathol | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the optimal oxygen pressure, duration, and frequency parameters for HBO | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260410- | Does reducing lipid droplets in microglia affect other AD pathologies beyond Aβ | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do BAMs and CD11c+ microglia specifically accumulate lipid droplets near Aβ | resolved | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link lipid droplet accumulation to impaired microglial | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does selenium nanoparticle modification specifically enhance quercetin's neu | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link gut microbiota changes to improved cognitive func | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |